期刊
ACS APPLIED MATERIALS & INTERFACES
卷 13, 期 29, 页码 33862-33873出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.1c07821
关键词
erythrocyte; plug and play; target drug delivery; prodrug; atherosclerosis
资金
- National Natural Science Foundation of China [31971301, 31971242, 12032007]
- Fundamental Research Funds for Central Universities [2020CDJQY-A061, 2018CDHB1B08]
- Chongqing Research Program of Basic research and Frontier Technology [cstc2019jcyj-zdxmX0028]
A nanoplatform based on red blood cells was developed for targeted drug delivery and controlled release for atherosclerosis treatment, addressing challenges such as low location specificity and side effects.
For atherosclerosis (AS) management, a therapeutic drug intervention is the most widely used strategy. However, there are some problems such as low location specificity, high intake, and side effects. Nanomedicine can prolong the half-life of drug solubilization, reduce toxic and side effects, and improve the distribution of drug objects. Herein, to overcome the challenges, an erythrocyte-based plug and play nanoplatform was developed by incorporating the vascular cell adhesion molecule-1 (VCAM-1) targeting and the acid stimulus responsibility. After the function moieties conjugated with DSPE-PEG, the targeting peptide and the acid-sensitive prodrug were conveniently integrated into red blood cells' surface for enhancing target AS drug delivery and controlling local drug release. As a proof of principle, a plug and play nanoplatform with targeted drug delivery and acid-control drug release is demonstrated, achieving a marked therapeutic effect for AS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据